

# Index

Note: Page numbers of chapter titles are in **bold face type**.

- ACUTE gout, treatment of, **133-143**
  - colchicine, 133-138
  - indomethacin, 140
  - other non-steroidal anti-inflammatory agents, 140-141
  - fenoprofen, 141
  - naproxen, 140-141
  - oxyphenbutazone, 138-140
  - phenylbutazone, 138-140
  - trimethylcolchicine acid (TMCA), 136-137
- Alcohol—
  - effect of acute intoxication, 29
  - effect of excess of, 29
  - effect of long-term ingestion of, 29
  - effect of, predisposing to gout, 29-30
- Allopurinol, 152-156
  - drug interactions with, 155
  - pyrimidine metabolism and, 156
  - other side effects of, 165
- Amidophosphoribosyltransferase, 7-8
  - activity of, 7-8
  - molecular weight, 7
  - control of activity, 8
- Anti-convulsants—
  - oxyphenbutazone therapy and, 139
  - phenylbutazone therapy and, 139
- Apatite crystal deposition—
  - inflammation associated with, 83-85
  - bursitis and, 83
  - tendonitis and, 83
- Arthritis—
  - apatite crystal-induced, 85-86
  - clinical patterns in pseudogout, **65-79**
    - also less well defined patterns of, 78-79
    - asymptomatic CPPD crystal deposition, 71
    - pseudogout, 65-66
    - pseudoneurotrophic joints, 71-78
    - pseudo-osteoarthritis, 70-71
    - pseudorheumatoid arthritis, 66-70
  - due to intra-articular injection of microcrystalline adrenocorticosteroid ester, 123-124
  - experimental studies, 124
  - observations in patients, 123-124
- gouty (monosodium urate deposition disease), 52-53, 105-117
  - crystal deposition in joints, 116-117
  - experimental studies, 111-116
  - observations in human gout, 105-110
  - hydroxyapatite associated, 125-127
  - experimental studies, 125
  - observations in human disease, 125
- Asymptomatic hyperuricaemia—
  - drug treatment of, 164-165
  - uricosurics, 164
  - xanthine oxidase inhibitors, 164-165
  - management of, **159-167**
  - renal function in patients with, 161-163
  - staging of treatment, 163
  - treatment of cases with renal insufficiency, 163-164
  - xanthine oxidase inhibitors in, 164
- BARBITURATES—
  - oxyphenbutazone therapy and, 139
  - phenylbutazone therapy and, 139
- Bartter's syndrome, 41
- Benzbromarone, 148-151
- Birefringence, 91-93
- CALCIUM pyrophosphate dihydrate (CPPD)
  - crystals, 96-97
- Calcium pyrophosphate dihydrate crystal deposition disease (pseudogout syndrome), **61-89**, 117-123
  - asymptomatic (Type E), 71
  - classification of, 62
  - clinical aspects of, **61-89**
  - crystal deposition in joints in relation to synovitis, 122-123
  - experimental studies, 122
  - hereditary, characteristics of, 63
  - leucocyte counts during, 118
  - observations in human disease, 117-122
  - pathogenesis of, 79-81
  - inorganic pyrophosphate and, 80

- Calcium pyrophosphate dihydrate crystal deposition disease—*cont.*  
 prevalence of, 64–65  
 pseudogout (Type A), 65–66  
 pseudoneurotrophic joints (Type F), 71  
 pseudorheumatoid arthritis (Type B), 66  
 pseudo-osteoarthritis (Types C and D), 70–71  
 treatment of, 82–83
- Calculi, 11  
 renal, 11  
 uric acid, 10  
 uricosuric therapy and, 45
- Chlorothiazide and hyperuricaemia, 42
- Cholesterol, relation with uric acid, 28–29
- Chronic hyperuricaemia, consequences of, 42–44
- Chronic tophaceous gout, 53–57  
 diagnosis of, 56–57
- Colchicine, 133–138
- Compensated polarizing microscope, *see* Microscope, compensated polarizing
- Crystal-induced synovitis, pathogenesis of, 81–82, **105–131**, *see also* Gouty arthritis and Calcium pyrophosphate dihydrate crystal deposition disease
- DIABETES, 30  
 anti-diabetic agents, phenylbutazone and oxyphenbutazone therapy and, 139
- Diuretic-induced hyperuricaemia, 37–50  
 chlorothiazide and, 42  
 ethacrynic acid and, 39  
 furosemide and, 39  
 prevention of, 45–47  
 saluretic diuretics and, 45–46  
 ticrynafen (tienilic acid) and, 46–47  
 treatment of, 44–45  
 uricosuric agents in, 46  
 probenecid, 46  
 sulphinyprazone, 46
- ENZYME abnormalities, 8–9, 13
- Ethacrynic acid, 37, 39
- FRUCTOSE, administration of, 12
- Furosemide, 37, 39
- GLUTAMINE, 6–7  
 enzyme abnormalities leading to increase in, 13
- Gout—  
 acute, treatment of, **133–143**  
 colchicine, 133–138  
 fenoprofen, 141  
 indomethacin, 140  
 naproxen, 140–141  
 oxyphenbutazone, 138–140  
 phenylbutazone, 138–140  
 trimethylcolchicinic acid (TMCA), 136–137  
 chronic tophaceous, 53–57  
 diagnosis of, 56–57  
 clinical approach to, 145–146  
 hypouricaemic agents in the treatment of, **145–158**, *see also* Hypouricaemic agents  
 obesity and, 25  
 pharmacology, 146–157  
 primary—  
 decreased clearance of uric acid in, 17–18  
 pathogenesis of hyperuricaemia in, **1–23**  
 Gouty arthritis (monosodium urate deposition disease), 52–53, 105–117  
 acute, 52–53  
 crystal deposition in joints, 116–117  
 diagnosis, 53  
 experimental studies, 111–116  
 observations in human gout, 105–110
- HYDROXYAPATITE associated arthritis, 125–127  
 experimental studies, 125  
 observations in human disease, 125
- Hyperuricaemia, 10–11
- Hyperuricaemia—  
 associated with gout, 159–160  
 asymptomatic, management of, **159–167**  
 drug treatment of, 164–165  
 uricosurics, 164  
 xanthine oxidase inhibitors, 164–165  
 renal function in patients with, 161–163  
 treatment of cases with renal insufficiency, 163–164  
 clinical manifestations of, **51–59**  
 definition of, 1–2  
 diuretic-induced, **37–50**, *see also* Diuretic-induced hyperuricaemia  
 pathogenesis of, 38–42  
 prevention of, 45–47  
 scope of the problem, 37–38  
 therapeutic aspects, 44–45  
 hypertriglyceridaemia and, 28  
 obesity and, **25–35**  
 pathogenesis of, in primary gout, **1–23**  
 Hypertriglyceridaemia—  
 relation with hyperuricaemia, 28
- Hypouricaemic agents in the treatment of gout, **145–158**  
 allopurinol, 152–156  
 benzbromarone, 145, 148–150  
 benziodarone, 145  
 clinical approach, 145–146  
 choice of hypouricaemic drug, 145–146  
 prophylactic and anti-inflammatory therapy, 146  
 halofenate, 145

- pharmacology, 146-157  
   combination therapy, 157  
   inhibitors of uric acid synthesis, 152-156  
   uricosurics, 146-152  
 probenecid, 145, 147, 151  
 sulphinpyrazone, 145, 148, 151  
 thiopurinol, 145  
 ticrynafen, 145  
 zoxazolamine, 145  
 Hypoxanthine, 2
- INDOMETHACIN**, 140  
 Inflammation, associated with apatite crystal deposition, 83-85  
 Inhibitors of uric acid synthesis, allopurinol, 152-156
- LIPIDS**, relation to body weight and uric acid, 27  
 Lipoproteinaemia, presence in gout patients, 28
- MICROSCOPE**, compensated polarizing, use of, 91-103  
   CPPD crystals, 96-97  
   birefringence, 91-93  
   compensator, 93-94  
   composite light path, 95-96  
   description, 91  
   elongation, 94-95  
   interference colours, 94  
   MSUM crystals, 96  
   other birefringent material, 97-102  
   x-ray diffraction studies and, 102  
 Monosodium urate monohydrate (MSUM) crystals, 61, 96  
 Monosodium urate deposition disease, *see* Gouty arthritis
- NATRIURETIC** compounds, 37  
 Non-steroidal anti-inflammatory agents, 140-141  
   fenoprofen, 141  
   naproxen, 140-141
- OBESITY** and hyperuricaemia, 25-35  
   influence of on serum uric acid, 30-31  
 Oxypurinol, 138-140  
   anti-diabetic agents and, 139
- PHENYLBUTAZONE**, 138-140  
   anti-diabetic agents and, 139  
 Phosphoribosyl pyrophosphate (PP ribose P), 6-8  
   synthetase, regulation of, 11  
 Polarizing microscope *see* Microscope, compensated polarizing  
 Probenecid, 47, 147, 151, 165
- Pseudogout *see* Calcium pyrophosphate dihydrate crystal deposition disease
- Purine metabolism**—  
   biosynthesis, 5-6  
   control of, 6-8  
   derangement leading to hyperuricaemia, 1  
   overproduction in man, 8, 11  
 Purine Symposium, 1976, 5
- RENAL** calculi, 11
- SEDATIVES**—  
   oxypurinol therapy and, 139  
   phenylbutazone therapy and, 139  
 Sulphinpyrazone, 46, 148, 151  
 Synovitis, pathogenesis of crystal-induced, 81-82, 105-131
- THIAZIDE** diuretics, 37  
 Thiopurinol, 145  
 Tolbutamide—  
   oxypurinol therapy and, 139  
   phenylbutazone therapy and, 139  
 Tophaceous gout, chronic, 53-57  
   diagnosis of, 56-57  
 Tranquillizers—  
   oxypurinol therapy and, 139  
   phenylbutazone therapy and, 139  
 Triglyceride levels, 27-29
- URIC** acid—  
   association of serum level with body weight, 25  
   calculi, 10  
   data before and after weight loss, 27  
   decreased clearance in primary gout, 17  
   decreased excretion, 14-19  
   effect of weight loss on serum level, 26-27, 30  
   excretion, control of by kidney, 14-16  
   increased production of, 5  
   increased production and decreased clearance of, 19-20  
   inhibitors of synthesis of, 152-156  
   mechanism of decreased clearance of, 19  
   nephrolithiasis, 57  
   synthesis and catabolism, 2  
 Uricosurics, 46, 146-152, 164  
   probenecid, 145, 147, 151  
   sulphinpyrazone, 145, 148, 151
- WARFARIN**—  
   oxypurinol therapy and, 139  
   phenylbutazone therapy and, 139
- XANTHINE**, 2, 165  
 Xanthine oxidase inhibitors, 164-165

I

N

Ac

(

(

(

(

(

(

(

(

(

(

(

Ad

All

An

An

(

(

(

(

An

An

An

(

# Index

Note: Page numbers of chapter titles are in **bold face type**.

- ACUTE anterior uveitis, **299-313**
  - clinical examination, 300
  - epidemiology, 300
    - of uveitis, 301
    - worldwide incidence of sarcoidosis, 301
  - idiopathic acute anterior uveitis, 302
  - immunology, 309
    - immune mechanisms, 310
  - mechanisms of blindness, 299
  - systemic disease associated with, 303
    - chronic inflammatory bowel disease, 304
    - juvenile chronic polyarthritis, 303
    - mucocutaneous syndromes, 305
    - ocular sarcoidosis, 305
    - Reiter's disease, 303
    - rheumatic disorders of the eye, 304
  - selective investigations, 308
    - blood tests, 309
    - histology, 309
    - radiography, 309
    - skin tests, 309
  - treatment of, 312
- Addison's disease, idiopathic, 246
- Alloantigens, B-cell, 187
- Amyloidosis, 370-371
- Ankylosing spondylitis, 197, 267-269, 281, 283
  - and immunogenetics, *see* Immunogenetics
  - and ankylosing spondylitis
  - chronic prostatitis in, 258
  - juvenile, 349
  - mild hypergammaglobulinaemia in, 260
  - of childhood onset, 338
  - presence of immunoglobulin in, 260
- Anterior uveitis, acute, *see* Acute anterior uveitis
- Antigens, serologically defined, 175
  - lymphocyte defined, 183
- Arthritis—
  - associated with chronic inflammatory bowel disease, 265
  - family association between chronic inflammatory bowel disease and ankylosing spondylitis, 268
  - familial occurrence of Crohn's disease, 269
  - familial occurrence of ulcerative colitis, 269
  - spinal involvement in inflammatory bowel disease, 268
- frequency of arthritis, 268
- enteropathic arthritis, 267
- HLA antigens in, 271-273
  - B27 in patients with inflammatory bowel disease and spinal involvement, 273
  - Crohn's disease, 271
  - enteropathic arthritis, 272
  - relationship with uveitis, 273
  - spinal disease, 272
  - ulcerative colitis, 271
- occurrence of spinal disease in patients and relatives, 269
- other genetic markers, 273
  - associations with other diseases, 274
  - blood groups, 273
  - evidence for influence of an environmental agent, 274
  - genetic interpretation, 275
  - glucose-6-phosphate dehydrogenase deficiency, 274
- peripheral arthritis—
  - in Crohn's disease, 266
  - in ulcerative colitis, 266
- spinal disease in inflammatory bowel disease, 267
- enteropathic, 272
  - in inflammatory bowel disease, 268
- of childhood onset—
  - chronic, recognizable sub-groups of, 336
  - HLA studies in onset of, 341
  - onset of, **333-343**
- of inflammatory bowel disease, 339
- peripheral, in Crohn's disease, 266
- peripheral, in ulcerative colitis, 266
- psoriatic, **281-298**, *see* Psoriatic arthritis

BEHÇET'S disease, 368-369  
syndrome, 305

- CELLULAR interactions, genetic regulation of, 209
- Childhood arthritis, chronic recognizable subgroups of, 336
- HLA studies of, 341
- Chlamidia, in the aetiology of Reiter's disease, 282, 286-287
- Circinate balanitis, in diagnosis of Reiter's disease, 288
- Coeliac disease, 243, 246
- Colitis, ulcerative, 267, 269
- Complement, 215-237
- biochemistry
  - biological activities and host defence, 220
  - clinical significance, 229
    - association of deficiency states with rheumatic diseases, 230
    - inherited deficiencies of complement proteins, 231
    - linkage of complement components with HLA, 232
    - recurrent infections due to impaired host defences, 229
  - and properdin, 215
  - complement proteins, inherited abnormalities, 216, 248
  - deficiencies, 223-229
  - reaction sequence, 218
    - classic activation, 218
    - properdin amplification, 219
    - properdin activation, 218
  - terminal sequence, 219
- Conjunctivitis, in Reiter's disease, 288
- Connective tissue diseases, some, preliminary HLA studies in, 372
- Crohn's disease, 266-269, 271, 275-276
- familial recurrence of, 269
- Chronic childhood arthritis, recognizable subgroups, 336
- Chronic inflammatory bowel disease, 304
- Chronic prostatitis in spondylising ankylosis, 258
- Chronic uveitis, 306
- Cushing's disease, 248
- DERMATITIS herpetiformis, 243, 246
- Dermatomyositis, 340
- Diabetes mellitus, 243
- Diarrhoea, as a precipitating event in Reiter's disease, 289
- Discoid lupus erythematosus, 367-368
- Doherty-Zinkernagel phenomenon, 247
- ENTEROPATHIC arthritis, 272
- Erythema nodosum, 282
- Eye, rheumatic disorders of, 304
- FORESTIER's disease, 371
- GBC—polymorphism, 189
- Gene frequencies, 177
- Gluten sensitive enteropathy, 197
- Gonococcal infection, association with arthritis, 283
- HAPLOTYPE frequencies, 177
- Hardy-Weinberg law, 177
- Heerfordt's syndrome, 306
- Herpes labialis, recurrent, 247
- Histocompatibility antigens— *see also* Immunogenetic factors
- and ankylosing spondylitis, 255-264
  - and arthritis of chronic inflammatory bowel disease, 265-280
  - and connective tissue diseases, 372
  - and childhood onset arthritis, 321-341
  - and natural selection, 250
  - and non-rheumatic diseases, 239-253
  - and other rheumatic diseases, 365-375
  - and rheumatoid arthritis, 321
  - and systemic lupus erythematosus, 366
  - family and population studies, *see* Immunogenetic factors, family and population studies
  - functions of, 320
  - genetic implications of in disease, 190
  - location of genes for, 319
  - lymphocyte defined antigens (HLA-D), 183
  - mechanism by which confer disease susceptibility, 245
  - complement abnormalities, 248
  - differentiation antigens, 249
  - immune response (Ir) determinants, 245
  - molecular mimicry, 248
  - receptor theory, 246
  - serologically defined antigens, 175
- IDIOPATHIC Addison's disease, 246
- Immune responsiveness, 197-214
- control of the immune response by MHC genes, 204
  - antigen used to demonstrate MHC-linked Ir genes, 204
  - cell types in which Ir gene product function is expressed, 207
  - genetic control of cell-mediated cytotoxicity, 210
  - genetic regulation of cellular interactions, 209
  - immune suppressor genes, 209
  - mapping of Ir genes to the I region of the MHC, 205
  - molecular nature of the T-lymphocyte receptor, 210
  - disease susceptibility and the MHC, 211
  - organization of the immune system, *see* Immune system, organization of

- Immune system, organization of, 197  
 macrophages, 203  
 other cells, 203  
 principal cells of, 199  
 thymus dependent (T) lymphocytes, 198  
 thymus independent (B) lymphocytes, 202
- Immunogenetic factors in rheumatoid arthritis, 315-332  
 association with HLA-D or Ia, 322  
 association with C2 deficiency  
 frequency of HLA-Dw4 in patients with rheumatoid arthritis, 322  
 associations with the major histocompatibility complex, 319  
 associations with HLA-A, B, or C, 321  
 frequency of HLA-A and B antigens in patients with JRA, 321  
 frequency of HLA-A and B antigens in rheumatoid arthritis, 321  
 functions of products of main histocompatibility complex, 320  
 HLA chromosomal region location, 319  
 clinical considerations, 316  
 family and population studies, 316  
 classical rheumatoid arthritis in adults, 317  
 family studies in rheumatoid arthritis, 317  
 twin studies in rheumatoid arthritis, 317  
 general considerations, 316  
 rheumatoid arthritis in children, 318  
 system lupus erythematosus, 318  
 thyroid autoimmunity, 318
- mechanisms, 323  
 effect on immune response, 324  
 high affinity of IgG rheumatoid factor, 326  
 linkage disequilibrium, 323  
 pathogenesis of rheumatoid arthritis, 325
- Immunogenetics and ankylosing spondylitis, 255-264  
 aberrant immunity, 259  
 immunogenetics of ankylosing spondylitis, 257  
 infectious agents, 258  
 mechanisms, 256  
 tissue lesion, 258
- Inflammatory bowel disease, arthritis of, 339,  
 see Arthritis, associated with inflammatory bowel disease
- Iridocyclitis, 340
- JUVENILE ankylosing spondylitis, 349  
 Juvenile chronic polyarthritis, 303  
 Juvenile diabetes mellitus, 197  
 Juvenile polyarthritis, classification of, 335  
 Juvenile psoriatic and Reiter's arthropathy and arthritis with inflammatory bowel disease, 350
- Juvenile rheumatoid arthritis (chronic polyarthritis, Still's disease), 333  
 criteria for diagnosis and classification, 334
- Löfgren's syndrome, 306  
 Lupus pernio, 306  
 Lymphadenopathy, in cases of Reiter's disease, 289  
 Lymphocytes—  
 thymus dependent (T), 198  
 thymus independent (B), 202  
 Lymphogranuloma inguinale, 283
- MACROPHAGES, 203  
 Major Histocompatibility complex (MHC) in man, 175-196, see Histocompatibility antigens  
 and disease susceptibility, 211  
 association of immunogenetic factors with, 319  
 B-cell alloantigens, 187  
 biological function of, 190  
 critical role of, 197  
 genetic implications of in disease, 190  
 linkage disequilibrium, 180  
 lymphocyte defined antigens (HLA-D), 183  
 phenotype and gene frequencies of the Central European caucasian population, 178  
 serologically defined antigens, 175
- Meningococcal infection, association with arthritis, 283
- MHC, see Major Histocompatibility Complex
- Molecular mimicry, 248  
 Mucocutaneous syndromes, 305  
 Multiple sclerosis, 197  
 Myasthenia gravis, 197  
 Mycoplasma, T-strain, 282, 286  
 Myocarditis—  
 in Reiter's disease, 288  
 in reactive arthritis, 284
- NASOPHARYNGEAL carcinoma, 197  
 Neurosarcoidosis, 306
- Non-rheumatic diseases—  
 association with HLA antigens, 239-253  
 genetics of, 243  
 susceptibility to, 245  
 complement abnormalities, 248  
 differentiation antigens, 249  
 immune response (Ir) determinants, 245  
 molecular mimicry, 248  
 receptor theory, 246  
 theoretical consequences of dominant Ir gene involvement in disease susceptibility, 246  
 nosology, 242

- OCULAR sarcoidosis, 305  
Osteitis condensans, 372
- PAGET's disease of bone, 371  
Pericarditis, in Reiter's disease, 288  
Peripheral arthritis, seronegative, 345-363  
  clinical splitting and lumping in, 346  
  definitive SPA; clinical groupings, 347-349  
  distinctive seronegative arthropathies, 349-351  
    juvenile ankylosing spondylitis, 349  
    juvenile psoriatic and Reiter's arthropathy, 350  
    pauciarticular chronic polyarthritis of children with chronic uveitis, 351  
    systemic Still's disease, 350  
  incomplete syndromes—'formes frustes', 351  
    incomplete Reiter's disease, 352  
    psoriatic arthropathy without psoriasis, 353  
    'true' seronegative rheumatoid arthritis, 351  
  mixed syndromes, 353  
  pre-definitive, 347  
  problems and challenges, 345-346  
    basis of interrelationships, 346  
    diagnosis, 345  
    isolation of significant data, 346  
    prognosis and management, 346  
  seronegative peripheral arthritis and recent immunological data, 354-358  
    aetiology, clinical expression of genetic factors, 358  
    HLA studies of sub-groups, 354  
    patterns of upper limb involvement, 356  
    value of immunogenetic data, 360  
  Phenotype frequencies, 177  
  Polyarthritis, juvenile, classification of, 335  
  Progressive systemic sclerosis, 368  
  Properdin systems, 215  
  Psoriasis, 248, 289  
    association with arthritis, 290  
  Psoriatic arthritis, 281-298  
    aetiology of, 291  
    clinical features of, 294  
    HLA antigens in, 291  
    radiological changes in, 295  
    sex ratio of patients with, 293  
    time relationship of skin signs to arthritis, 293  
  Pulmonary fibrosis, 306
- REACTIVE arthritis, 281-298, 340  
  and uveitis, 284  
  clinical course of, 284  
  clinical features of, 283  
  host factors in, 282  
  infections known to be associated with, 282  
  myocarditis seen with, 284
- Recurrent herpes labialis, 247  
Reiter's disease, 281-298  
  anterior uveitis associated with systemic disease, 303  
  arthritis in, 288  
  circinate balanitis, 288  
  clinical course, 289  
  clinical manifestation of, 288  
  conjunctivitis in, 288  
  genetic aspects, 285  
  incomplete, 352  
  keratoderma blennorrhagica, 288  
  myocarditis in, 288  
  pericarditis in, 288  
  syndrome, 339  
  skin lesions in, 288  
  triggering factors, 286  
Rheumatic diseases, other, HLA studies in, 365-375  
Rheumatic disorders of the eye, 304  
Rheumatic fever, 369  
Rheumatoid arthritis, immunogenetic factors in, 315-332  
  associations with major histocompatibility complex, 319  
  clinical considerations, 316  
  family and population studies, 316  
  juvenile, 333  
  mechanisms, 323  
  tests for, 284  
Rubella arthritis, 283
- SACROILIITIS, 281, 283  
  asymptomatic, 267  
Salmonella infections in aetiology of reactive arthritis, 282, 283  
Sarcoidosis, 300  
  HLA antigens in, 307  
  investigative routine, 307  
  regular, 305  
  worldwide incidence of, 301  
Sarcoid uveitis, 300  
Sclerosis, progressive systemic, 368  
Seronegative peripheral arthritis, 281, 345-363, see Peripheral arthritis, seronegative  
Shigella infection in aetiology of reactive arthritis, 282  
Sjögren's syndrome, 370  
Sjögren-like syndrome, 306  
Skin lesions, in Reiter's disease, 288  
Specific immunological tolerance, 197  
Spinal disease, 272  
  in inflammatory bowel disease, 267  
  occurrence in patients and relatives, 269  
Sphenomegaly, in some cases of Reiter's disease, 289  
Stevens-Johnson syndrome, 305  
Still's disease, 333, 350



- Systemic lupus erythematosus, 305, 365-368  
  HLA studies of caucasian patients with, 366  
  summary of all HLA studies in patients with, 367
- Systemic sclerosis, progressive systemic, 368
- TONSILLITIS, presented by *Yersinia* infected patients, 284
- Tendovaginitis, 284
- ULCERATIVE colitis, 267, 269
- Uveitis, 267  
  anterior acute, see Acute anterior uveitis
- VASCULAR permeability, changes in, 215
- Vertebral ankylosing hyperostosis (Forestier's Disease), 371
- YERSINIA* enterocolitica in aetiology of reactive arthritis, 282-283, 284



# Index

Note: Page numbers of chapter titles are in **bold face type**.

- AMYLOID fibril proteins, characterization of, 589–598
  - experimental models of protein AA-type amyloidosis, 593–595
  - extraction procedure, 590–591
  - immunoglobulin light chain type, 595–596
  - in medullary carcinoma of thyroid, 596
  - nomenclature, 589
  - protein AA of secondary amyloid fibrils, 591–592
  - protein SAA, precursor of protein AA? 592–593
- Amyloidosis, 534–535
  - the heart in, 493–495
- Anaemia, 433–466
  - bone marrow findings in, 434
  - due to blood loss, 441–442
  - erythrocyte survival, 440–441
  - erythropoietin, 439–440
  - ferrokinetics, 434–439
    - radioisotope studies in, 437–438
  - haemodilution, 441
  - iron absorption, 439
  - lactoferrin, 433–434
  - macrocytosis, 444
  - principal abnormalities encountered in, 434
  - reticuloendothelial iron storage, 442
  - treatment of, 445–446
- Analgesic nephropathy, 539–540
- Aortic valve lesions, 487–491
- Aortitis, 492
- Arteritis, coronary, 495
- Ascorbic acid, importance of in reduction of haem and ferritin, 436
- Aspirin—
  - and liver disease, 532
  - and ocular disease, 523
- Atrioventricular dissociation, complete, 492
- BLOOD changes in RA, *see* Haematological changes
- Bone involvement in RA, **403–420**
  - historical aspects, 403
  - hyperparathyroidism, 416
  - osteomalacia, 416
- osteoporosis—
  - generalized, 405–411
    - aetiology of, 410
    - assessment of, 407
    - chronic inflammation in, 410–411
    - incidence and severity, 407–411
    - postmenopausal, 417
  - localized, and erosions, 411–416
    - biochemical abnormalities in aetiology of, 414–416
    - bone resorbing activity in, 413
    - pathogenesis of, 412–413
    - therapy for, 416–417
- CAPLAN'S syndrome, 557
- Cardiac involvement, *see* Heart disorders
- Cardiac tamponade, 479–482
  - treatment of, 481
- Carpal tunnel syndrome, 446
- Chafford-Still syndrome, 446
- Chloroquine and hydroxychloroquine, and ocular disease, 522
- Coagulation abnormalities, 455–456
- Conduction defects, 492–493
  - complete atrioventricular dissociation, 492
  - first degree heart block, 492–493
- Constrictive pericarditis, 482–485
  - treatment of, 485
- Coronary arteritis, 495
- Corticosteroids and ocular disease, 521
- DRUGS—
  - haematological disease due to, 458
  - liver disease due to, 531–533
  - ocular disease due to, 521–523
  - renal disease due to, 535–538
- EOSINOPHILIA, 457
- Episcleritis, 508
  - differential diagnosis of, 510
  - treatment of, 518
- Erosions, and localized osteoporosis, 411–416
  - biochemical abnormalities in aetiology of, 414–416
  - pathogenesis of, 412–413

- Erythrocyte survival in anaemia, 440-441  
Erythropoietin, 439-440
- FELTY'S syndrome**, 421, 433, 446-454  
  blood changes in, 447  
  bone marrow changes in, 447  
  humoral factors and granulocyte antibodies in, 448-451  
  leucokinetics in, 447-449  
  splenic histopathology, 451-452  
  treatment of, 452-454  
    lithium carbonate in, 454  
    splenectomy in, 453  
    indications for, 453  
  testosterone in, 454
- Ferritin, 436
- Ferrokinetics, in anaemia, 434-439
- Fibre atrophy, 572-574
- Fibrosing alveolitis, 551-555  
  clinical features of, 551-553  
  immunology of, 554-555  
  immunofluorescent studies in, 555  
  pathology of, 553-554  
  treatment and response, 553
- Follicular hyperplasia, 423-425  
  differential diagnosis of, 426-427
- GLOMERULAR changes in RA**, 533-534
- Gold therapy—  
  and liver disease, 532  
  and ocular disease, 523  
  and renal disease, 535
- HAEMODILUTION**, 441
- Haemosiderin, 436
- Haematological changes in rheumatic disease, 433-463  
  anaemia, *see* Anaemia  
  coagulation abnormalities, 455-456  
  drug-induced, 458  
  eosinophilia, 457  
  Felty's syndrome, *see* Felty's syndrome  
  hyperviscosity syndrome, 457  
  neutrophil function, disorders of, 454-455  
  thrombocytosis and thrombocytopenia, 456
- Heart disorders in RA**, 467-500  
  amyloidosis, 493-495  
  aortitis, 492  
  clinical studies, 469  
  conduction defects, 492-493  
    complete atrioventricular dissociation, 492  
    first degree heart block, 492-493  
  coincidental, 467  
  coronary arteritis, 495  
  diagnosis, 472  
  myocarditis, 493  
  pericarditis, 473-486  
    clinical features of, 476  
    complications of, 478-486  
      associated lesions, 485-486  
      cardiac tamponade, 479-482  
      constrictive pericarditis, 482-485  
      pericardial effusions, 478  
      in juvenile chronic polyarthritis, 476-478  
      pathology, 474  
  primary, 467  
  secondary, 467  
  valvular lesions, 486-491  
    associated with other complications of RA, 491  
    of aortic valve, 487-491  
    of mitral valve, 491
- Hepatic complications of RA, *see* Liver disease in RA
- Hydroxychloroquine and chloroquine, and ocular disease, 522
- Hyperparathyroidism, 416
- Hyperplasia, reactive, *see* Reactive hyperplasia
- Hyperviscosity syndrome, 457
- IATROGENIC abnormalities—**  
  haematological, 458  
  hepatic, 531-533  
  ocular, 521-523  
    cataract, 521  
    glaucoma, 522  
    infection, 521  
  renal, 535-538
- Ibuprofen, and ocular disease, 523
- Indomethacin—  
  and liver disease, 532  
  and ocular disease, 523
- Iridocyclitis and juvenile chronic polyarthritis, 519-521  
  acute, 519  
  chronic, 519-521
- JUVENILE chronic polyarthritis—**  
  and iridocyclitis, 519-521  
  and pericarditis, 476-478
- KERATOCONJUNCTIVITIS sicca**, 502-507  
  diagnosis, 505-506  
  dry eyes, treatment of, 507  
  Kidney, *see* Renal disease in RA
- LACTOFERRIN**, 443-444
- Liver disease in RA, 527-547  
  drug-induced, 531-533  
    gold and, 532  
    ibufenac and, 532  
    indomethacin and, 532  
    paracetamol and, 532  
    salicylates and, 532  
  histology of, 530-531
- Lung disease, *see* Pulmonary disease in RA

- Lymphadenopathy and Sjogren's syndrome, 421-432  
 classical features of, 421  
 histopathological features of, 422-430  
 malignant lymphoproliferative disorders, 428-430  
 pseudolymphoma, 427-428  
 reactive hyperplasia, 423-427  
 follicular, 423-425  
 interfollicular, 425  
 sinusal, 425-426  
 Lymphoproliferative disorders, malignant, 428-430
- MACROGLOBULINAEMIA, Waldenström's, 422  
 Malignant lymphoproliferative disorders, 428  
 Mitral valve lesions, 491  
 Muscle abnormalities in RA, 567, *see also*  
 Myopathy; Neuromuscular  
 manifestations of RA  
 Myocarditis, 493  
 Myopathy—  
 inflammatory, 569-572  
 minimal lesion, 569
- NECROTIZING scleritis, 512-514  
 scleromalacia perforans, 514  
 Neuromuscular manifestations of RA, 565-588  
 clinical manifestations of, 566-567  
 histological types of, 569-585  
 cross-over syndromes (Type V), 580-582  
 fibre atrophy (Type III-Type II), 572-574  
 inflammatory myopathy (Type II), 569-572  
 minimal lesion myopathy (Type I), 569  
 neurogenic syndromes (Type IV), 574-580  
 vasculitis (Type VI), 582-583  
 muscle biopsy analysis, 566  
 results, 567  
 Neutrophil function, disorders of, 454-455  
 Nodules—  
 necrobiotic, 555-557  
 Caplan's syndrome, 557  
 pathology, 557  
 rheumatoid, 385-390  
 Nodular scleritis, 510-512
- OBLITERATIVE broncho-bronchiolitis, 558  
 Ocular complications of RA, 501-526  
 drug-induced, 521-523  
 aspirin and, 523  
 chloroquine and hydroxychloroquine and, 522  
 corticosteroids and, 521  
 gold and, 523  
 ibuprofen and, 523  
 indomethacin and, 523  
 phenylbutazone and, 523  
 episcleritis, 508  
 differential diagnosis of, 510  
 treatment of, 518  
 iridocyclitis, and juvenile chronic poly-  
 arthritis, 519-521  
 acute, 519  
 chronic, 519-521  
 keratoconjunctivitis sicca, 502-507  
 diagnosis, 505-506  
 dry eyes, treatment of, 507  
 scleritis, 508-519  
 associated disease, 517-518  
 classification of, 509  
 complications, 516-517  
 course of, 516-517  
 differential diagnosis, 510  
 diffuse, 512  
 necrotizing, 512-514  
 scleromalacia perforans, 514  
 nodular, 510-512  
 pathology, 509  
 posterior, 514-516  
 treatment of, 518-519  
 Oestrogen therapy, in postmenopausal os-  
 teoporosis, 417  
 Osteomalacia, 416  
 Osteoporosis—  
 generalized, 405-411  
 aetiology of, 410  
 assessment of, 407  
 chronic inflammation in, 410-411  
 incidence and severity of, 407-410  
 postmenopausal, 417  
 severe spinal, 406  
 localized, and erosions, 411-416  
 biochemical abnormalities in aetiology  
 of, 414-416  
 bone resorbing activity in, 413  
 pathogenesis of, 412-413
- PARACETAMOL, and liver disease, 532  
 Penicillamine, and renal disease, 535  
 Pericarditis—  
 clinical features, 476  
 complications of, 478-486  
 associated lesions, 485-486  
 cardiac tamponade, 479-482  
 treatment of, 481  
 constrictive pericarditis, 482-485  
 treatment of, 485  
 pericardial effusions, 478  
 in juvenile chronic polyarthritis, 476-478  
 pathology, 474  
 Phenylbutazone, and ocular disease, 523  
 Pleural effusions, 558  
 Polyarteritis nodosa, 566

- Polyarthritis and lung disease, *see* Pulmonary disease in RA
- Pseudolymphomas, 422, 427-428
- Pulmonary disease in RA, 549-564
- antinuclear antibody in, 599
  - in fibrosing alveolitis, 554
  - in inorganic dust disease, 560
  - fibrosing alveolitis, 551-555
    - clinical features of, 551-553
    - immunology, 554-555
    - immunofluorescent studies in, 555
    - pathology, 553-554
    - treatment and response, 553
  - immunopathogenesis of, 558-559
  - necrobiotic nodules, 555-557
    - Caplan's syndrome, 557
    - pathology, 557
  - obliterative broncho-bronchiolitis, 558
  - pleural effusions, 557
  - polyarthritis and, 550
  - rheumatoid factors in, 599
    - in fibrosing alveolitis, 554
    - in inorganic dust disease, 560
- REACTIVE hyperplasia, 423-427
- follicular, 423-425
    - differential diagnosis of, 426-427
  - interfollicular, 425
  - sinusal, 425-426
- Renal disease in RA, 527-541
- amyloidosis, 534-535
  - analgesic nephropathy, 539-540
    - pathogenesis, 540
    - prognosis, 540
    - symptoms, 539-540
  - drug-induced, 535-538
    - gold and, 535
    - penicillamine and, 535
  - glomerular changes in, 533-534
  - tubular dysfunction in, 538
- Rheumatoid arthritis—
- general features, 385-400
  - nodules, 385-390
    - intracutaneous, 389
    - sites of, 386
  - subcutaneous, 385
  - systemic manifestations, *see under individual systems*
  - vasculitis, 390-400
    - clinical features of, 391-394
    - pathology, 344-396, 399-400
- SCLERITIS, 508-519
- associated disease, 517-518
  - classification of, 509
  - complications, 516-517
  - course of, 516-517
  - differential diagnosis, 510
  - diffuse, 512
  - necrotizing, 512-514
    - scleromalacia perforans, 514
  - nodular, 512-514
  - pathology, 509
  - posterior, 514-516
  - treatment of, 518-519
- Scleroderma, 565
- Scleromalacia perforans, 514
- Sjögren's syndrome—
- keratoconjunctivitis sicca and, 503-507
  - lymphadenopathy and, 421-432, *see* Lymphadenopathy and Sjögren's syndrome
- Still's disease, 446
- Systemic lupus erythematosus, 565
- THROMBOSIS and thrombocytopenia, 456
- Tubular dysfunction, renal, 538
- VALVULAR lesions, 486-491
- associated with other complications of RA, 491
  - of aortic valve, 487-491
  - of mitral valve, 491
- Vasculitis, 390-400, 582-583
- clinical features, 391
  - complicated by leg ulcers, 397
  - pathology, 344-396, 399-400
- WALDENSTRÖM'S macroglobulinaemia, 422

INDEX

er in-

507  
2, see  
Ögren's

56

of RA,

422